CTR9 and breast carcinoma: Collectively, our study uncovers a unique mechanism by which a transcriptional elongation factor demarcates the PRC2-mediated H3K27me3 domains in breast cancer cells and provides a molecular basis for therapeutically targeting CTR9-low breast tumors with EZH2 inhibitors.